

Appl. No. 09/917,963  
Amdt. dated September 3, 2003  
Reply to Office Action of June 17, 2003

#### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

##### Listing of Claims:

1(Canceled).

2(Currently Amended). The compound of claim 1 11 which is an antisense oligonucleotide.

3(Canceled).

4(Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5(Original). The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6(Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7(Original). The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Appl. No. 09/917,963  
Amdt. dated September 3, 2003  
Reply to Office Action of June 17, 2003

8(Original). . . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9(Original). The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10(Original). The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11(Previously Presented). A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule of SEQ ID NO: 3 encoding human microsomal triglyceride transfer protein, wherein said active site is a sequence spanning nucleotides 3133 to 3152 of SEQ ID NO: 3 and wherein said compound inhibits expression of said molecule encoding said protein.

12(Currently Amended). A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier or diluent.

13(Original). The composition of claim 12 further comprising a colloidal dispersion system.

14(Original). The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Appl. No. 09/917,963  
Amdt. dated September 3, 2003  
Reply to Office Action of June 17, 2003

15(Currently Amended). A method of inhibiting the expression of human microsomal triglyceride transfer protein in cells or tissues *in vitro* comprising contacting said cells or tissues with the compound of claim 4 11 so that expression of human microsomal triglyceride transfer protein is inhibited.

16-20(Canceled).